Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)

Publication | Open Access

DOI Full Paper Access

190

Citations

References

2006

Year

Wolfram Pönisch, Paris S. Mitrou, K Merkle, Michael Herold, G. Wilhelm, Klaus Dachselt, Peter C. Richter, Veronika Schirmer, Antina Schulze, R. Šubert,

Journal of Cancer Research and Clinical Oncology

Hematological MalignancyMedicineMetronomic TherapyHematologyClinical TrialsTreatment FailureMultiple Myeloma ResultsPharmacotherapyPhase Iii StudyOncologyRadiation OncologyCancer ResearchHealth Sciences